Matthias Liechti

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamide) in adult patients with attention deficit hyperactivity disorder. The company said it expects...

Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective serotonin uptake inhibitor, known as escitalopram, with an acute response to psilocybin in humans. The publication is based...

MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), announced Thursday that it had obtained authorization from the local Swiss ethics committee to conduct the first clinical trial on mescaline. What Happened The psychedelic medicine biotech company noted that the study will examine...

Psychedelic medicine biotech company MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) reported Monday the results of a study on MDMA dosing optimization utilizing personalized medicine. The study was conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland. The company said it...

In an exclusive to Benzinga, Mind Medicine (MindMed) Inc (OTC: MMEDF), a leading medicine biotech company in psychedelics, on Tuesday revealed the introduction of a division known as Albert, to help research and develop an integrated platform for delivering psychedelic medicines, experiential...

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. Versión en Español en El Planteo. MindMed Inks Deal With Switzerland...